ArticleFrontiers in cellular and infection microbiology2021
Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to
Article in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 79 citations in OpenAlex.
- Association of nasopharyngealMicrobiology spectrum · 2026Article
- Nanobiosensors: A Potential Tool to Decipher the Nexus Between SARS-CoV-2 Infection and Gut Dysbiosis.Sensors (Basel, Switzerland) · 2026Review
- Assessment of the bacterial community of the human upper respiratory tract in patients affected by Covid-19.Genetics and molecular biology · 2026Article
- SARS-CoV-2 lineages and naso-oropharyngeal bacterial communities in COVID-19 reinfection: A study in West Java, Indonesia.Narra J · 2025Article
- Oral microbiota and respiratory diseases: advances and perspectives.Clinical microbiology reviews · 2025Review
- Age- and disease severity-associated changes in the nasopharyngeal microbiota of COVID-19 patients.iScience · 2025Article
- Respiratory microbiome and metabolome features associate disease severity and the need for doxycycline treatment in children with macrolide-resistantFrontiers in cellular and infection microbiology · 2025Article
- Dysbiosis of the oropharyngeal microbiota in COVID-19: distinct profiles in patients with severe respiratory symptoms.Journal of oral microbiology · 2025Article
- Oropharyngeal resistome remains stable during COVID-19 therapy, while fecal resistome shifts toward a less diverse resistotype.iScience · 2024Article
- The healing process of diabetic ulcers correlates with changes in the cutaneous microbiota.Scientific reports · 2024Article
- Metagenomic next-generation sequencing of nasopharyngeal microbiota in COVID-19 patients with different disease severities.Microbiology spectrum · 2024Article
- Potential Beneficial Effects of Naringin and Naringenin on Long COVID-A Review of the Literature.Microorganisms · 2024Review
- Herpesviruses and SARS-CoV-2: Viral Association with Oral Inflammatory Diseases.Pathogens (Basel, Switzerland) · 2024Review
- Hospital antimicrobial stewardship: profiling the oral microbiome after exposure to COVID-19 and antibiotics.Frontiers in microbiology · 2024Article
- Deciphering the microbial landscape of lower respiratory tract infections: insights from metagenomics and machine learning.Frontiers in cellular and infection microbiology · 2024Article
- Microbiome Profiling in Bladder Cancer Patients Using the First-morning Urine Sample.European urology open science · 2024Article
- The nasopharyngeal microbiome in COVID-19.Emerging microbes & infections · 2023Article
- Changes in sputum microbiota during treatment for nontuberculous mycobacterial pulmonary disease.Scientific reports · 2023Article
- Bacterial Biomarkers of the Oropharyngeal and Oral Cavity during SARS-CoV-2 Infection.Microorganisms · 2023Article
- Specific nasopharyngeal Corynebacterium strains serve as gatekeepers against SARS-CoV-2 infection.GeroScience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the pandemic Coronavirus Disease 2019 (COVID-19). This virus is highly transmissible among individuals through both droplets and aerosol leading to determine severe pneumonia. Among the various factors that can influence both the onset of disease and the severity of its complications, the microbiome composition has also been investigated. Recent evidence showed the possible relationship between gut, lung, nasopharyngeal, or oral microbiome and COVID-19, but very little is known about it. Therefore, we aimed to verify the relationships between nasopharyngeal microbiome and the development of either COVID-19 or the severity of symptoms. To this purpose, we analyzed, by next generation sequencing, the hypervariable V1-V2-V3 regions of the bacterial 16S rRNA in nasopharyngeal swabs from SARS-CoV-2 infected patients (n=18) and control (CO) individuals (n=12) using Microbiota solution A (Arrow Diagnostics). We found a significant lower abundance of Proteobacteria and Fusobacteria in COVID-19 patients in respect to CO (p=0.003 and p<0.0001, respectively) from the phylum up to the genus (p<0.001). The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.